Australian Pharmaceutical Patents Expiring December 2013
Below is a report from IP Organisers (an independent service company of Phillips Ormonde Fitzpatrick) detailing Australian Pharmaceutical Patents which will expire in the next month.
Matrix tablet permitting the sustained release of indapamide after oral administration
Abstract
The invention relates to a matrix tablet for the sustained release of indapamide which ensures a continuous and uniform release of the active principle after oral administration.
Biocompatible viscoelastic gel slurries, their preparation and use
Abstract
Biocompatible viscoelastic gel slurries formed from a polymeric gel, preferably a hyaluronan or a derivative thereof such as hylan swollen in an aqueous medium and a fluid phase which is an aqueous solution of a polymer which may also but not necessarily be a hyaluronan or derivative thereof. Also disclosed are methods of making such slurries, controlling their rheological properties and the uses thereof.
1, 4, 7, 10-tetraazacyclodedecane butyltriols, processes for their production and pharmaceutical agents containing them
Abstract
1,4,7,10-Tetraazacyclododecane-butyltriols of the general formula IA in which R<1> independently of one another denotes hydrogen or a metal ion equivalent and R<2> denotes a butyltriol radical, and their salts with organic or inorganic bases or amino acids are useful pharmaceutical agents.
Unique antigenic epitopes on IgE-bearing B lymphocytes
Abstract
Unique antigenic epitopes of IgE (designated ige.b1 which are present on IgE-bearing B lymphocytes but not basophils are described. One class of ige.b1 epitopes are at or near the FcεR binding site on IgE. Another class of ige.b1 epitopes are associated with the extracellular segment of the domain of ε chains which anchor IgE to the B cell membrane (ε.mb/ec)). Monoclonal antibodies which bind to the ige.b1 epitopes are useful to treat IgE-mediated allergies. The monoclonal antibodies, either alone or as cytotoxin-conjugated immunotoxins, can be used to reduce or deplete IgE-producing B cells in allergy sufferers. Monoclonal antibodies against the idiotypes of the ige.b1 specific antibodies or peptides expressing the epitopes can be used to actively immunize allergy sufferers to attain the same results of administering the monoclonal antibodies.
